Biomarkers for early detection of Alzheimer pathology

C. M. Clark; C. Davatzikos; A. Borthakur; A. Newberg; S. Leight; V. M.Y. Lee; J. Q. Trojanowski

doi:10.1159/000109754

Biomarkers for early detection of Alzheimer pathology

C. M. Clark, C. Davatzikos, A. Borthakur, A. Newberg, S. Leight, V. M.Y. Lee, J. Q. Trojanowski

Research output: Contribution to journal › Review article › peer-review

76 Scopus citations

Abstract

The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T₁ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

Original language	English (US)
Pages (from-to)	11-18
Number of pages	8
Journal	NeuroSignals
Volume	16
Issue number	1
DOIs	https://doi.org/10.1159/000109754
State	Published - Dec 2007
Externally published	Yes

Keywords

Alzheimer's disease
Biomarkers
Diagnosis
Neurodegenerative disease

ASJC Scopus subject areas

Neurology
Developmental Neuroscience
Cellular and Molecular Neuroscience

Access to Document

10.1159/000109754

Cite this

@article{33d72f07b95e4ade863777a47ba24c49,

title = "Biomarkers for early detection of Alzheimer pathology",

abstract = "The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.",

keywords = "Alzheimer's disease, Biomarkers, Diagnosis, Neurodegenerative disease",

author = "Clark, {C. M.} and C. Davatzikos and A. Borthakur and A. Newberg and S. Leight and Lee, {V. M.Y.} and Trojanowski, {J. Q.}",

year = "2007",

month = dec,

doi = "10.1159/000109754",

language = "English (US)",

volume = "16",

pages = "11--18",

journal = "NeuroSignals",

issn = "1424-862X",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Biomarkers for early detection of Alzheimer pathology

AU - Clark, C. M.

AU - Davatzikos, C.

AU - Borthakur, A.

AU - Newberg, A.

AU - Leight, S.

AU - Lee, V. M.Y.

AU - Trojanowski, J. Q.

PY - 2007/12

Y1 - 2007/12

N2 - The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

AB - The increasing prevalence of Alzheimer's disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer's disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

KW - Alzheimer's disease

KW - Biomarkers

KW - Diagnosis

KW - Neurodegenerative disease

UR - http://www.scopus.com/inward/record.url?scp=37349048311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349048311&partnerID=8YFLogxK

U2 - 10.1159/000109754

DO - 10.1159/000109754

M3 - Review article

C2 - 18097155

AN - SCOPUS:37349048311

SN - 1424-862X

VL - 16

SP - 11

EP - 18

JO - NeuroSignals

JF - NeuroSignals

IS - 1

ER -

Biomarkers for early detection of Alzheimer pathology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this